UK Interim Clinical Commissioning Policy for tocilizumab has been updated to cover a wider group of hospitalised COVID-19 positive patients, DHSC

NHS trusts/health boards are recommended to consider prescribing single dose of tocilizumab to eligible hospitalised patients with COVID-19 pneumonia, typically as adjuvant treatment to dexamethasone as standard of care, following announcement of findings of RECOVERY trial.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news